In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
The authors proved that the drug was able to cross the blood-brain barrier in a concentration that was effective.
Why were adverse events reported through an alternative reporting channel as opposed to a more transparent means?
The researchers wrote that “genetic counseling must be further explored to find an optimal balance of clinical quality with increased access and financial sustainability.”
The presence of CHEK2 or PALB2 variants in Hispanic women is enough to warrant the addition of an annual breast MRI, said study authors.
Improvements to PFS and “clinically meaningful reductions in daily corticosteroid use” were said to be linked to the addition of bevacizumab in glioblastoma.
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Adjuvant ipilimumab may improve overall survival in patients with resected high-risk melanoma.
Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
One of the study’s primary objectives was to detect an association between homologous repair deficiency and pathologic response.
